Contents

Supplementary Table 1: Individual patient's characteristics at the midpoint of each decile2
Supplementary Table 2: The estimated probability that a delayed abnormal blood test would have caused a more serious condition with 5-ASA
Supplementary Table 3: The estimated costs and Quality Adjusted Life Years (QALY) losses associated with each condition derived from the literature ¹⁻¹¹ . Please see health economics methods.
Supplementary Table 4: Disaggregated results in the base case
Supplementary Table 5: Aggregated Results in the base case compared with current 3-month monitoring
Figure S1: Study population selection criteria for model development
Figure S2: Model validation cohort: Study population selection criteria7
Figure S3: Nelson–Aalen cumulative hazard estimates for 5-ASA discontinuation associated with individual blood-test abnormalities*
Figure S4: Distribution of predicted risk in the model development cohort at 5 years9
Figure S5: Calibration plot of a prognostic model for 5-ASA discontinuation with abnormal monitoring blood-test results at 5-years in the development cohort ¹ 10
Figure S6: Calibration plot of a prognostic model for 5-ASA discontinuation with abnormal monitoring blood-test results at 5-years in the validation cohort ¹
Figure S7: Distribution of predicted risk in the model validation cohort at 5 years
Figure S8: Calibration of a prognostic model for 5-ASA discontinuation with abnormal monitoring blood-test results at 1 year in the validation cohort ¹
Figure S9: Calibration of a prognostic model for 5-ASA discontinuation with abnormal monitoring blood-test results at 2 years in the validation cohort ¹
Figure S10: Calibration of a prognostic model for 5-ASA discontinuation with abnormal monitoring blood-test results at 3 years in the validation cohort ¹
Figure S11: Calibration of a prognostic model for 5-ASA discontinuation with abnormal monitoring blood-test results at 4 years in the validation cohort ¹
Figure S12: Incremental net monetary benefit results when the risks of serious conditions estimated by clinicians were tripled

Decile	Age (yr.)	Sex	BMI (kg/m²)	Alcohol	Disease	DM	CKD -3	IS drug	Statins	Carb/ Val	Paracetamol	BTA	Cumulative probability of outcome %
1	30-35	М	24.6	Low	IBD	No	No	No	No	No	No	No	3.13
2	35-40	М	23.8	Low	IBD	No	No	No	No	No	No	No	3.18
3	30-35	F	28.0	Low	IBD	No	No	No	No	No	No	No	3.23
4	50-55	F	19.1	Non- drinker	IBD	No	No	No	No	No	No	No	3.29
5	65-70	F	28.5	Low	IBD	No	No	No	No	No	Yes	No	3.39
6	65-70	М	26.1	Low	IBD	No	No	No	Yes	No	Yes	No	3.88
7	50-55	М	27.9	Non- drinker	IBD	No	No	No	No	No	No	No	4.55
8	40-45	М	22.9	Non- drinker	IBD	Yes	No	No	No	No	Yes	No	5.48
9	65-70	М	31.0	Low	IBD	No	Yes	Aza/6- MP	No	No	Yes	No	6.08
10	60-65	М	30.7	Low	IBD	Yes	Yes	No	Yes	No	No	No	8.62

Supplementary Table 1: Individual patient's characteristics at the midpoint of each decile.

Aza/6-MP: Azathioprine/6-Mercaptopurine; BMI: Body Mass Index; BTA: Blood Test abnormalities within 6 months of primary care 5-ASA prescription; CKD-3: Chronic Kidney Disease stage 3; Carb/Val: carbamazepine/valproate; DM: diabetes mellitus; F: female; IS immunosuppressive; M: male, ±5-year age band. Exact age not shown for anonymity.

Supplementary Table 2: The estimated probability that a delayed abnormal blood test would have caused a more serious condition with 5-ASA.

Adverse Event	6-monthly monitoring	Annual monitoring	Two-yearly monitoring		
Acute kidney injury*					
Acute liver failure*					
Anaemia*					
Chronic kidney disease	0.001	0.001	0.008		
Cirrhosis*					
Drug-induced liver injury	0.001	0.001	0.001		
Early fibrosis*					
Low neutrophil count	0.0001	0.0002	0.0004		
plus sepsis					
Neutropenic sepsis	0.0001	0.0002	0.0004		
Thrombocytopenia					
requiring hospitalisation*					
Thrombocytopenia with					
superficial bleeding*					

*The clinical experts did not think that 5-ASA causes these outcomes.

Supplementary Table 3: The estimated costs and Quality Adjusted Life Years (QALY) losses associated with each condition derived from the literature¹⁻¹¹. Please see health economics methods.

Condition	Costs (£)	QALY loss
Acute Kidney Injury	2022	0.014
Acute Liver Failure	3352	0.651
Anaemia	465	0.001
Chronic Kidney Disease	26,083	1.308
Cirrhosis	21,700	3.042
Drug-Induced Liver Injury	3352	0.651
Early Fibrosis	0	0.075 ⁺
Low neutrophil count plus sepsis	2313	2.490
Neutropenic Sepsis	9456	2.490
Thrombocytopenia requiring hospitalisation	1018	0.016
Thrombocytopenia with superficial bleeding	133	0.001

⁺per 6 months unidentified

	Manitoria Americana Manitoria Costa Abramal bload Costa accessionad CALV laces															
	Monitoring Appointments				Nonitoring Costs			Abriorniai biood						QALTIOSSES		
					Saved compared			results identified			with late			associated with late		
					with current 3-			late compared with			identification of			identification of		
					month monitoring			current 3-month			abnormal blood			abnormal blood		
					(£)			monitoring			results (£)			results		
De	3-	6-	Ann	Bien	6-	Ann	Bien	6-	Ann	Bien	6-	Ann	Bien	6-	Ann	Bien
cile	mon	mo	ual	nial	mo	ual	nial	mo	ual	nial	mo	ual	nial	mo	ual	nial
	ths	nth			nth			nth			nth			nth		
1	19.6	9.8	4.9	1.99	185	278	331.	0.0	0.0	0.02	0.4	0.7	5.94	0.0	0.0	0.00
	7	4	3		.99	.98	62	16	24	9	6	3		000	001	04
2	19.6	9.8	4.9	1.99	185	278	331.	0.0	0.0	0.02	0.4	0.7	5.96	0.0	0.0	0.00
	7	4	3		.98	.96	59	16	25	9	6	3		000	001	04
3	19.6	9.8	4.9	1.99	185	278	331.	0.0	0.0	0.02	0.4	0.7	6.01	0.0	0.0	0.00
	7	4	3		.95	.92	54	16	25	9	7	4		000	001	04
4	19.6	9.8	4.9	1.99	185	278	331.	0.0	0.0	0.03	0.4	0.7	6.14	0.0	0.0	0.00
	6	4	3		.88	.81	42	17	25	0	8	6		000	001	04
5	19.6	9.8	4.9	1.99	185	278	331.	0.0	0.0	0.03	0.4	0.7	6.29	0.0	0.0	0.00
	5	3	3		.80	.69	28	17	26	1	9	7		000	001	04
6	19.6	9.8	4.9	1.99	185	277	330.	0.0	0.0	0.03	0.5	0.8	7.26	0.0	0.0	0.00
	0	1	1		.28	.91	34	20	30	6	6	9		000	001	04
7	19.5	9.7	4.9	1.99	184	276	328.	0.0	0.0	0.04	0.6	1.0	8.74	0.0	0.0	0.00
	2	7	0		.48	.70	90	24	36	3	8	8		001	001	05
8	19.4	9.7	4.8	1.98	183	275	327.	0.0	0.0	0.04	0.7	1.2	9.97	0.0	0.0	0.00
	5	4	8		.82	.71	71	27	43	9	7	3		001	001	06
9	19.3	9.7	4.8	1.98	183	274	326.	0.0	0.0	0.05	0.8	1.4	11.4	0.0	0.0	0.00
	6	0	6		.01	.50	26	31	47	6	9	1	6	001	001	07
10	19.1	9.5	4.8	1.97	180	270	321.	0.0	0.0	0.08	1.2	1.9	16.0	0.0	0.0	0.00
	1	8	1		.54	.79	82	43	66	0	4	7	0	001	002	10

Supplementary Table 4: Disaggregated results in the base case

Supplementary Table 5: Aggregated Results in the base case compared with current 3month monitoring

	Net	Cost Savings	s (£)	Net QALY losses						
Decile	6-month	Annual	Biennial	6-month	Annual	Biennial				
1	185.53	278.25	325.68	0.0000	0.0001	0.0004				
2	185.51	278.22	325.63	0.0000	0.0001	0.0004				
3	185.48	278.18	325.53	0.0000	0.0001	0.0004				
4	185.40	278.05	325.27	0.0000	0.0001	0.0004				
5	185.31	277.92	324.99	0.0000	0.0001	0.0004				
6	184.71	277.02	323.08	0.0000	0.0001	0.0004				
7	183.80	275.63	320.16	0.0001	0.0001	0.0005				
8	183.04	274.49	317.75	0.0001	0.0001	0.0006				
9	182.12	273.09	314.80	0.0001	0.0001	0.0007				
10	179.29	268.82	305.83	0.0001	0.0002	0.0010				

Figure S1: Study population selection criteria for model development



Aminosalicylates were balsalazide, mesalazine and olsalazine, CKD: chronic kidney disease, GP: General practice, CPRD: Clinical Practice Research Datalink.

Figure S2: Model validation cohort: Study population selection criteria



Aminosalicylates were balsalazide, mesalazine and Olsalazine, CKD: chronic kidney disease, GP: General practice, CPRD: Clinical Practice Research Datalink.



Figure S3: Nelson–Aalen cumulative hazard estimates for 5-ASA discontinuation associated with individual blood-test abnormalities*.

* cytopenia defined as white blood cells (WBCs) $<3.5 \times 10^{9}$ /l or neutrophils $<1.6 \times 10^{9}$ /l or platelets $<140 \times 10^{9}$ /l; ALT/AST >100 IU/l



Figure S4: Distribution of predicted risk in the model development cohort at 5 years

Figure S5: Calibration plot of a prognostic model for 5-ASA discontinuation with abnormal monitoring blood-test results at 5-years in the development cohort¹



¹Data from a single imputed dataset; So(t=5) = 0.971

Figure S6: Calibration plot of a prognostic model for 5-ASA discontinuation with abnormal monitoring blood-test results at 5-years in the validation cohort¹



¹Data from a single imputed dataset; So(t=5) = 0.971





Figure S8: Calibration of a prognostic model for 5-ASA discontinuation with abnormal monitoring blood-test results at 1 year in the validation cohort¹

A: Calibration plot



¹Data from a single imputed dataset was used; $S_0(t_{=1}) = 0.993$

B: Smoothed calibration curve

Figure S9: Calibration of a prognostic model for 5-ASA discontinuation with abnormal monitoring blood-test results at 2 years in the validation cohort¹

A. Calibration plot



B. Smoothed calibration curve

¹Data from a single imputed dataset was used; $S_0(t_{=2}) = 0.986$

Figure S10: Calibration of a prognostic model for 5-ASA discontinuation with abnormal monitoring blood-test results at 3 years in the validation cohort¹

A. Calibration plot



B. Smoothed calibration curve

Data from a single imputed dataset was used; $S_0(t_{=3}) = 0.980$

Figure S11: Calibration of a prognostic model for 5-ASA discontinuation with abnormal monitoring blood-test results at 4 years in the validation cohort¹

.15 Slope = 0.902 C-statistic = 0.608 4 3 ς. observed risk I .2 Observed Reference Groups 0 95% Cls .05 Υ. 0 0 Т .1 .2 predicted risk .3 0 .4 .05 .15 .1 0 Expected

B. Smoothed calibration curve

Data from a single imputed dataset was used; $S_0(t_{=4})=0.976$

A. Calibration plot



